Asia’s growing demand for fertility treatments a boon to industry leader Monash IVF
A pioneer in premium assisted reproductive technologies and fertility science, Monash is well-placed to meet in vitro fertilisation demands in the region
Increasing infertility, delayed childbearing and various lifestyle changes are some of the prevailing characteristics among the growing middle class in Asia-Pacific that significantly contribute to the growing in vitro fertilisation (IVF) industry. As a global pioneer, with more than 40 years of expertise in premium assisted reproductive technologies and fertility science,
Monash IVF Group is well-placed to play a vital role in meeting the IVF demands in the region.
“Monash IVF is a significant player on the world fertility stage because of our strong history, academic developments, scientific firsts and commercial know-how,” says Dr Richard Henshaw, senior fertility specialist and executive director. “Our world’s firsts include the first IVF pregnancy in 1973, the first frozen embryo pregnancy in 1983, and the first single sperm microinjection pregnancy in 1993. We are at the forefront of genetic sciences with our breakthrough non-invasive genetic screening research.”
Monash IVF’s scientific leadership bench regularly tops worldwide rankings and is a testament to its scientific expertise. The group also consistently invests in furthering science through Monash IVF Research and Education Foundation, leveraging a large network of eminent professors and internationally recognised scientists.
Monash IVF started its international expansion in 2013 with the acquisition of KL Fertility Centre and opened its new state-of-the-art, 12,000 sq ft facility in Malaysia in May this year. This flagship operation provides for much needed capacity expansion, caters to medical tourism across Asia, and is an excellent springboard for Monash IVF’s regional expansion plans.
As it pursues its Asian expansion, Monash IVF welcomes like-minded regional clinic, academic and research partnerships. The group is particularly focused on China, where it seeks collaborations with top-tier specialised women’s health and maternity hospitals and experienced health care management corporations.
“China presents a unique opportunity for Monash IVF to partner with reputable organisations and create world-class clinics that adhere to the highest standards, accreditations and success rates,” says Jan Lagerwij, head of international business development. “We bring extensive expertise in areas such as quality and regulatory, operations, training, science, and research and development to ultimately deliver exceptional results, care and patient experience.”